explore -WSS

explore

author：fashion 2025-09-28 22:53:37 - browse：77

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Failure, not just success, should guide future doctors

leisure time

WSS

Cigna to pay $172 million to settle Medicare Advantage fraud probe

It was time to plan for my old age. If only I could stop crying

Kaiser Permanente unions announce official strike date

Election results set back Medicaid expansion plans

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Menendez indictment could see pharma lose a key ally

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

Ionis has late

Continuity nursing helped my family in our darkest PICU moments

Pennsylvania man bitten on the head by bear during attack in his garage

DIEP, the 'gold standard' of breast reconstruction, is under threat

Inequities make cancer less preventable for women: report

Alkermes shareholders re

Doctors are clamoring for more clarity on Paxlovid prescribing

Dobbs anniversary: the lost opportunity of abortion as health care

Flash flood warnings continue for parts of Missouri, Illinois

hotspot

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Trump used to be more articulate. What could explain the change?

Mindstrong's demise and the future of mental health care

'Brian's Song' at 50 still offers lessons about cancer for today

FDA seeks to regulate lab

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

Wikipedia

leisure time

knowledge

focus